Illuminant Surgical vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 37)
Illuminant Surgical logo

Illuminant Surgical

EmergingHealthcare

General

Medical device company projecting CT/MRI anatomy directly onto patients during surgery for real-time guidance; YC-backed $500K raised at $750K-$900K revenue with SIGGRAPH 2025 research presentation.

AI VisibilityBeta
Overall Score
D37
Category Rank
#496 of 596
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
42
Perplexity
33
Gemini
31

About

Illuminant Surgical is a medical device company developing Skylight — a real-time anatomical projection system that displays medical imaging data (CT scans, MRI, ultrasound) directly onto the patient's body surface during surgery, giving surgeons continuous visual guidance about subsurface anatomy without looking away from the operative field. Founded in 2022 and backed by Y Combinator with $500,000+ raised from YC, the US National Science Foundation, and angel investors, Illuminant generated $750,000-$900,000 in revenue in 2024 with an 18-person team and presented Skylight research at SIGGRAPH 2025.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

37
Overall Score
90
#496
Category Rank
#2
68
AI Consensus
83
stable
Trend
up
42
ChatGPT
92
33
Perplexity
93
31
Gemini
89
43
Claude
96
36
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.